Tuesday, November 9, 2010: 12:45 PM
Grand Ballroom B (Salt Palace Convention Center)
Quality Risk Assessments (QRA) for API and DP processes are mostly performed independently to examine the chemical or formulation processes themselves in terms of process risk and potential process control strategies. However, many of the process risks in a formulation process can be attributed to the properties of the API. In my talk, I will examine the potential application of QRA's to examine the overall risk across the API-DP boundary.
See more of this Session: Quality-by-Design (QbD) Round Table Discussion Session: An Integrated and Science-Based Approach for Quality by Design (QbD) Implementation in Pharmaceutical Industry
See more of this Group/Topical: Topical i : Comprehensive Quality by Design in Pharmaceutical Development and Manufacture
See more of this Group/Topical: Topical i : Comprehensive Quality by Design in Pharmaceutical Development and Manufacture
![[ Visit Client Website ]](images/banner.gif)